Search
for
Did you mean Hand-Foot Syndrome?
Sort by
Research 30 of 1000+
- Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin
- Prophylaxis and Management of Skin Toxicities
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Chemotherapy and the Skin: Understanding Dermatologic Side Effects
- Skin toxicity of anti‐cancer therapy
- Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis
- Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Cutaneous toxicities of cancer therapy
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
- Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Chemotherapy and Cutaneous Drug Reactions
- Clinical development and management of adverse events associated with FGFR inhibitors
- Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
- DERMATOLOGICAL ADVERSE EFFECTS OF CHEMOTHERAPEUTIC AGENTS: EXPERIENCE FROM A TERTIARY CENTRE
- Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- Cutaneous Reactions to Chemotherapeutic Agents
- The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
- Topoisomerase‐Interacting Agents
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Comparative Outcomes of Cutaneous Vesicostomy Versus Cystoscopic Valve Ablation in the Initial Management of Posterior Urethral Valves
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy